Lisa Conroy

Lisa Conroy is the Director of Communications at Antidote. She is a seasoned health communications strategist dedicated to understanding the reasons people make the health choices they do, and determining what that means in terms of how scientific data should be communicated. Prior to her role at Antidote, Lisa ran the TEDMED Great Challenges program, a public health initiative funded by RWJF. She also has experience working in pharmaceutical public relations in the areas of respiratory diseases, oncology, and HIV. Lisa holds an MPH from Columbia and a BA in English and International Studies from Northwestern.

SCOPE 2020: Balancing technology with human touch, for results

Later this month, our team will be making the trip to Orlando to attend this year’s SCOPE Summit. We’re looking forward to connecting with some of the best minds in clinical operations to share best practices that continue to drive innovation in the space. 

Continue reading

How clinical trial matching software can amp up your recruitment

Clinical trial matching software is one of the newer developments in the clinical research space. This technology matches patients with clinical trials they may qualify for in a process that’s simple both for patients and sponsors. Typically, sponsors work directly with clinical trial matching software companies to find solutions for their specific clinical trial portfolios. 

Continue reading

How patient recruitment materials can make or break your campaign

Patient recruitment materials developed by clinical trial recruitment companies have to achieve more than simply passing an IRB’s careful inspection. While guideline adherence is critical, it’s just as important that materials capture patient interest, answer key questions, and guide would-be participants to the next step toward your trial. 

Continue reading

What 4,000 patients taught us about driving diversity in clinical trials

In order for medications to work effectively for all who need them, clinical trials need to include a diverse cross-section of the population. And yet, though nearly 40% of the population in the United States are racial and ethnic minorities, estimated rates of research participation for these groups range from 2% to 16%. 

Continue reading

5 ways to drive innovative patient recruitment in 2020

It's a new year and a new decade with much promise, especially in drug development. New digital technologies, from telemedicine to wearables and new medical devices will continue to change the industry. AI and machine learning hold the exciting potential to accelerate new treatments and potential cures. With all that technology has changed within the drug development process, there are many more ...

Continue reading

COPD Awareness Month: Looking Towards a Cure

This month, we observe COPD Awareness Month — a time to educate on the disease while reflecting on how far we’ve come in terms of treatment, and how clinical research is the path to a cure. Chronic Obstructive Pulmonary Disease, or COPD, is the third leading disease-related cause of death in the United states. Nearly 16 million people are living with it, and many more may have it without knowing ...

Continue reading

How We Delivered 60% of All US Randomizations in a Recent Trial [Case Study]

Primary biliary cholangitis (PBC) is an autoimmune condition that causes progressive destruction of the bile ducts. Current treatment options focus on delaying progression and managing complications, but it can be difficult to live with the symptoms, like fatigue, itchy skin, and pain, as well.

Continue reading

Alzheimer’s Awareness Month: A Time to Focus on Research

November is National Alzheimer’s Disease Awareness Month. It’s a month where we stop to think about the 5.8 million Americans living with Alzheimers, and how someone in the US develops the disease every 65 seconds. It’s a time to provide extra support to the more than 16 million Americans who perform the role of caregiver, devoting an estimated 18.5 billion hours of care to those with Alzheimer’s ...

Continue reading

We Asked 4,000 Patients about Clinical Trials: Here's What Matters Most [Webinar Recap]

Last week, Antidote’s Head of Partnerships, Lindsey Wahlstrom-Edwards, hosted a webinar in which she shared the results of our patient survey. In the survey, we asked nearly 4,000 patients and caregivers about their attitudes and opinions of clinical research to find out what matters most, and how we can better engage patients from all walks of life in medical research. 

Continue reading

The New Rules for Clinical Trials Patient Engagement: An ERT Podcast

Recently, Antidote’s Director of Business Development, Rachel Lind, was featured on the fantastic ERT podcast, “Trial Better.” She and host Jason Eger, Director of Organizational Readiness at ERT, discussed the changing landscape of patient recruitment, the ways in which patients are becoming their own advocates, the importance of diversity in clinical trials, and reducing site burden through ...

Continue reading

Get our latest posts in your inbox.